Astellas Files Personalized Tarceva In First-line Lung Cancer With FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
If successful, filing in EGFR-positive patients could give Roche/Astellas’ Tarceva a commercial boost, broadening erlotinib’s role in non-small-cell lung cancer.